Popular GLP-1 weight-loss medications like Ozempic and Wegovy can trigger rapid weight loss and severe caloric restriction, raising concerns among medical experts that extreme deficits might deprive the brain of vital energy, nutrients, and structural stability during treatment.
As prescription GLP-1 weight-loss drugs continue to surge in popularity, medical researchers are examining both their profound metabolic benefits and their potential physiological toll. While patients using medications such as semaglutide and tirzepatide often shed substantial amounts of weight—with people taking the popular GLP-1 drugs shedding an average of one-quarter of their body weight according to one study cited by Nature—experts emphasize that the human brain relies on a continuous, uninterrupted supply of fuel to maintain its physical integrity.
Energy Availability and the Physical Limits of Brain Reserve
According to Dr. Tommy Wood, a professor of pediatrics and neuroscience at the University of Washington, the impact of these medications on cognitive health depends entirely on where a patient sits on the spectrum of energy availability. Speaking at the annual fitness and wellness festival Strong NY in New York City, Wood noted via Fox News Digital that the brain functions as the most energy-hungry organ in the body.
Brain reserve—representing the physical amount and integrity of brain tissue—follows a bell-shaped curve relative to the body’s energy intake. Excess energy caused by obesity, high blood sugar, and metabolic disease damages blood vessels and contributes to insulin resistance, lowering the brain’s resilience over time. In these elevated metabolic states, GLP-1 medications provide clear cognitive and physical benefits by lowering blood pressure and improving blood sugar control. However, Daniel Drucker, an endocrinologist at the University of Toronto in Canada whose work aided in the development of GLP-1 drugs, noted to Nature that there is tremendous heterogeneity in patient responses, pointing out that 10–15% of people using the drugs lose minimal weight or none at all, adding that researchers do not yet understand that variation.
Structural Risks and Individual Variability
While some individuals experience minimal results, other factors such as biological sex also influence treatment outcomes. According to clinical trials and real-world data highlighted in Nature, women tend to lose more weight than men on GLP-1 medications. A 2024 study of postmenopausal women taking semaglutide and a February study on tirzepatide both found that women receiving hormone-replacement therapy lost more weight than those without it, suggesting to Drucker that the female sex hormone oestrogen might enhance the effects of obesity drugs.
Beyond demographic and hormonal influences, the lower end of the energy spectrum introduces structural vulnerabilities. When individuals drastically reduce their food intake for extended periods while taking weight-loss medications, severe caloric deficits can force the central nervous system to experience chronic under-eating.
“There was a study that looked at the brains of people who ran a marathon … because the marathon is so energy-intensive, the white matter in the brain actually shrank during a marathon because the brain didn’t have enough energy … so it was eating its own white matter”
Dr. Tommy Wood, professor of pediatrics and neuroscience at the University of Washington, via Fox News Digital
Although marathon runners’ brains subsequently recovered after resting and refueling, the extreme demand demonstrates that the brain will actively decrease its volume when starved of adequate fuel. Prolonged caloric restriction can simultaneously deprive the central nervous system of essential structural nutrients required for long-term health.
Nuanced Realities of Lean Muscle Loss
Concerns regarding muscle mass reduction during GLP-1 therapy also require careful clinical nuance. Wood explained via Fox News Digital that a portion of the initial lean mass lost during rapid weight reduction consists of accumulated fat stored inside muscle tissue rather than functional muscle fibers.
Because embedded intramuscular fat diminishes muscle quality, shedding this internal fat can actually improve overall muscle functioning despite the reduction in physical dimensions. Risks emerge only when patients maintain extreme, extended caloric restriction without consuming sufficient protein and core neuro-nutrients.
Safeguarding Cognitive Health During Treatment
To protect cognitive function and maintain physical health while utilizing weight-loss treatments, medical professionals advise careful dietary and lifestyle management. Ensuring an adequate intake of core neuro-nutrients—including B vitamins such as B12, folate, and B6, alongside vitamin D, iron, and omega-3 fatty acids—prevents long-term cognitive impairment, according to Wood via Fox News Digital.
“If you’re not eating enough, you’re not getting the nutrients that are critical for the brain. So you’re not getting in enough omega-3 fats, which we know are really important. You’re not getting enough iron and protein and all those kinds of things.”
Dr. Tommy Wood, professor of pediatrics and neuroscience at the University of Washington, via Fox News Digital
Experts recommend pairing pharmaceutical weight-loss regimens with resistance training at least twice a week to preserve functional muscle mass and stimulate essential brain growth factors. While the medications offer significant therapeutic value for metabolic health, patients must ensure they avoid pushing dietary restrictions to extremes that compromise neurological nutrition.